Life Sciences Viii, L.P.Fhm... Net Worth

The estimated Net Worth of Life Sciences Viii, L.P.Fhm... is at least $157 Thousand dollars as of 18 January 2019. Life Fhm owns over 372,439 units of Aptinyx Inc stock worth over $156,858 and over the last 6 years Life sold APTX stock worth over $0.

Life Fhm APTX stock SEC Form 4 insiders trading

Life has made over 2 trades of the Aptinyx Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Life bought 372,439 units of APTX stock worth $1,999,997 on 18 January 2019.

The largest trade Life's ever made was buying 372,439 units of Aptinyx Inc stock on 18 January 2019 worth over $1,999,997. On average, Life trades about 261,220 units every 104 days since 2018. As of 18 January 2019 Life still owns at least 2,571,450 units of Aptinyx Inc stock.

You can see the complete history of Life Fhm stock trades at the bottom of the page.

Insiders trading at Aptinyx Inc

Over the last 6 years, insiders at Aptinyx Inc have traded over $0 worth of Aptinyx Inc stock and bought 10,337,357 units worth $55,328,087 . The most active insiders traders include Street Partners Llc Adams, Patrick G Enright, and James N Topper. On average, Aptinyx Inc executives and independent directors trade stock every 35 days with the average trade being worth of $18,161. The most recent stock trade was executed by Joan W. Miller on 13 January 2022, trading 17,700 units of APTX stock currently worth $50,091.

What does Aptinyx Inc do?

welcome to our company page and thank you for your interest in aptinyx inc. aptinyx is a biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system. aptinyx has a proven platform for discovering proprietary compounds that work through a novel mechanism: modulation of the nmda receptor to enhance pathways involved with nerve cell communication. our goal is to rapidly advance our most promising drug candidates into clinical development for indications with high unmet medical need. at aptinyx, we remain committed and responsive to our employees. we offer an engaging work environment, challenging work assignments, and competitive compensation and benefits. if you are interested in learning more, please visit our website at www.aptinyx.com.

Complete history of Life Fhm stock trades at Alpine Immune Sciences Inc and Aptinyx Inc

Aptinyx Inc executives and stock owners

Aptinyx Inc executives and other stock owners filed with the SEC include:

• Norbert Riedel,
  President, Chief Executive Officer, Director
• Ashish Khanna,
  Chief Financial Officer, Chief Business Officer
• Andrew Kidd,
  Chief Operating Officer
• Dr. Norbert G. Riedel,
  Exec. Chairman
• Dr. Andrew D. Kidd B.M. B.Ch., M.D.,
  CEO, Pres & Director
• Ashish Khanna,
  CFO & Chief Bus. Officer
• Henry Gosebruch,
  Independent Director
• Rachel Sherman,
  Independent Director
• Robert Hombach,
  Independent Director
• Patrick Enright,
  Independent Chairman of the Board
• Adam Koppel,
  Independent Director
• Elisha Gould,
  Independent Director
• Tim Noffke,
  VP of Program Management & Chief of Staff
• Dr. Harald Murck M.D., Ph.D.,
  VP of Clinical & Medical Affairs
• Patrick Flavin,
  Sr. Mang. of Corp. Devel. & Investor Relations
• Dr. Kathryn King Ph.D.,
  Sr. VP of Clinical & CMC Operations
• Molly Dir,
  VP of HR
• Juan Estupinan,
  VP of Fin. & Accounting and Controller
• Capital Life Sciences Inves...,
  
• Gilmore Neil O'neill,
  
• Terry P Gould,
  
• Leaf Venture Management Iii...,
  
• David Houck,
  Chief Development Officer
• Torsten M. Madsen,
  Chief Medical Officer
• James N Topper,
  Director
• Life Sciences Viii, L.P.Fhm...,
  
• Capital Partners Ii, Llc Ta...,
  
• Wilbur H Gantz,
  Director
• Joseph R. Moskal,
  Chief Scientific Officer
• Street Partners Llc Adams,
  10% owner
• Liam Ratcliffe,
  Director
• Joan W. Miller,